Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 7 | 2016 | 206 | 1.110 |
Why?
|
| Antipsychotic Agents | 6 | 2015 | 247 | 0.990 |
Why?
|
| Psychiatry | 2 | 2021 | 112 | 0.800 |
Why?
|
| Telemedicine | 2 | 2021 | 700 | 0.720 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 17 | 0.660 |
Why?
|
| Depressive Disorder, Major | 3 | 2008 | 439 | 0.650 |
Why?
|
| Patient Participation | 1 | 2019 | 146 | 0.600 |
Why?
|
| Community-Based Participatory Research | 1 | 2019 | 133 | 0.600 |
Why?
|
| Mental Health | 1 | 2019 | 278 | 0.550 |
Why?
|
| Medication Adherence | 2 | 2010 | 335 | 0.550 |
Why?
|
| Mental Health Services | 2 | 2016 | 199 | 0.550 |
Why?
|
| Psychotherapy | 2 | 2015 | 253 | 0.500 |
Why?
|
| Mental Disorders | 4 | 2022 | 659 | 0.480 |
Why?
|
| Schizophrenic Psychology | 2 | 2014 | 53 | 0.470 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 711 | 0.460 |
Why?
|
| Length of Stay | 1 | 2015 | 780 | 0.400 |
Why?
|
| Psychotropic Drugs | 2 | 2010 | 83 | 0.350 |
Why?
|
| Chronic Disease | 3 | 2010 | 1330 | 0.320 |
Why?
|
| Pandemics | 2 | 2021 | 352 | 0.300 |
Why?
|
| Water Intoxication | 1 | 2007 | 1 | 0.300 |
Why?
|
| Polyuria | 1 | 2007 | 2 | 0.300 |
Why?
|
| Psychophysiologic Disorders | 1 | 2007 | 20 | 0.290 |
Why?
|
| Hyponatremia | 1 | 2007 | 20 | 0.290 |
Why?
|
| Drinking | 1 | 2007 | 35 | 0.290 |
Why?
|
| Motivation | 1 | 2010 | 561 | 0.260 |
Why?
|
| Health Status | 1 | 2008 | 429 | 0.250 |
Why?
|
| Metabolic Syndrome | 1 | 2006 | 191 | 0.230 |
Why?
|
| Patient Compliance | 1 | 2006 | 402 | 0.220 |
Why?
|
| Humans | 20 | 2022 | 68618 | 0.210 |
Why?
|
| Comorbidity | 5 | 2022 | 1426 | 0.210 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 940 | 0.180 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 782 | 0.180 |
Why?
|
| Interview, Psychological | 3 | 2016 | 113 | 0.180 |
Why?
|
| Bipolar Disorder | 2 | 2015 | 307 | 0.170 |
Why?
|
| Adult | 10 | 2022 | 21403 | 0.150 |
Why?
|
| Risk Factors | 4 | 2010 | 5731 | 0.150 |
Why?
|
| Patient Education as Topic | 2 | 2010 | 425 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2010 | 2279 | 0.140 |
Why?
|
| Psychological Tests | 1 | 2016 | 96 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2016 | 75 | 0.130 |
Why?
|
| Risperidone | 1 | 2015 | 48 | 0.130 |
Why?
|
| Thiazoles | 1 | 2015 | 95 | 0.120 |
Why?
|
| Outpatients | 1 | 2015 | 127 | 0.120 |
Why?
|
| Health Services Research | 1 | 2016 | 209 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2008 | 1140 | 0.120 |
Why?
|
| Delayed-Action Preparations | 2 | 2015 | 120 | 0.120 |
Why?
|
| Health Policy | 1 | 2016 | 221 | 0.110 |
Why?
|
| Piperazines | 1 | 2015 | 206 | 0.110 |
Why?
|
| Inpatients | 1 | 2015 | 208 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 521 | 0.110 |
Why?
|
| Female | 10 | 2016 | 38074 | 0.110 |
Why?
|
| Male | 9 | 2016 | 37321 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2015 | 346 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 931 | 0.100 |
Why?
|
| South Carolina | 2 | 2015 | 2752 | 0.090 |
Why?
|
| Cognition | 1 | 2014 | 513 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2010 | 53 | 0.090 |
Why?
|
| Judgment | 1 | 2010 | 40 | 0.090 |
Why?
|
| Professional-Family Relations | 1 | 2010 | 45 | 0.090 |
Why?
|
| Medication Therapy Management | 1 | 2010 | 32 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2010 | 70 | 0.090 |
Why?
|
| Awareness | 1 | 2010 | 81 | 0.090 |
Why?
|
| United States | 4 | 2022 | 7367 | 0.080 |
Why?
|
| Middle Aged | 4 | 2015 | 21147 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 567 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 261 | 0.080 |
Why?
|
| Polypharmacy | 1 | 2007 | 31 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 123 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 767 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 438 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2009 | 502 | 0.070 |
Why?
|
| Alcoholism | 1 | 2015 | 1109 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2007 | 157 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2009 | 384 | 0.070 |
Why?
|
| Citalopram | 1 | 2006 | 30 | 0.070 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2006 | 54 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2008 | 298 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 186 | 0.070 |
Why?
|
| Suicide, Attempted | 1 | 2006 | 72 | 0.070 |
Why?
|
| Weight Gain | 1 | 2006 | 135 | 0.060 |
Why?
|
| Pain | 1 | 2008 | 472 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 286 | 0.060 |
Why?
|
| Health Surveys | 1 | 2006 | 489 | 0.060 |
Why?
|
| Young Adult | 1 | 2015 | 5717 | 0.060 |
Why?
|
| Family | 1 | 2006 | 293 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 2800 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1851 | 0.050 |
Why?
|
| Preexisting Condition Coverage | 1 | 2022 | 4 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1753 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2006 | 703 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2077 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 201 | 0.040 |
Why?
|
| Adolescent | 2 | 2008 | 8912 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 1242 | 0.040 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2016 | 8 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2016 | 58 | 0.030 |
Why?
|
| Stroke | 1 | 2008 | 2163 | 0.030 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 260 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2016 | 230 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 7029 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 196 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2014 | 201 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 622 | 0.030 |
Why?
|
| Aged | 1 | 2008 | 14862 | 0.030 |
Why?
|
| Psychometrics | 1 | 2014 | 514 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1738 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2014 | 342 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 7277 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3259 | 0.020 |
Why?
|
| Georgia | 1 | 2009 | 161 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 119 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 157 | 0.020 |
Why?
|
| Poverty | 1 | 2007 | 219 | 0.020 |
Why?
|
| Curriculum | 1 | 2009 | 575 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2007 | 1342 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 2334 | 0.010 |
Why?
|
| Child | 1 | 2007 | 6405 | 0.010 |
Why?
|